• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Philips Acquires SpectraWAVE to “Double Down” on AI-Powered Coronary Imaging

by Fred Pennic 12/15/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Philips Acquires SpectraWAVE to “Double Down” on AI-Powered Coronary Imaging

What You Should Know: 

– Philips has agreed to acquire SpectraWAVE, Inc., a move designed to bolster its leadership in image-guided therapy by integrating SpectraWAVE’s AI-powered coronary imaging and physiology assessments into the Philips Azurion platform.

– The acquisition adds critical next-generation capabilities, including DeepOCT (optical coherence tomography) and wire-free Fractional Flow Reserve (FFR), to Philips’ existing portfolio. 

– The strategic expansion aims to improve outcomes for the 300 million people worldwide affecting by coronary artery disease by giving clinicians a more comprehensive, single-platform toolkit for interventions.

Philips Bets Big on AI-Driven Cardiac Imaging with SpectraWAVE Acquisition

In the high-stakes world of interventional cardiology, seconds matter, and image clarity is the currency of survival. Today, Royal Philips (NYSE: PHG) signaled a significant consolidation of that currency, announcing its acquisition of SpectraWAVE, Inc., a Bedford, Massachusetts-based innovator in intravascular imaging.

While financial terms remain undisclosed, the strategic intent is crystal clear: Philips is moving to lock down the coronary intervention market by plugging SpectraWAVE’s AI-driven sensing technology directly into its ubiquitous Azurion platform.

For industry watchers, this is more than a bolt-on acquisition. It represents a shift toward “multimodality” in a single setting—bringing structure, composition, and physiology data together to treat the world’s most common heart disease.

Doubling Down on the Azurion Ecosystem

Roy Jakobs, CEO of Royal Philips, described the move as “doubling down on image-guided therapy.” This is not hyperbole. Philips’ Azurion platform is already used to treat over 7.6 million patients annually across 80 countries. By acquiring SpectraWAVE, Philips is addressing a specific gap in the high-definition imaging space.

Modern percutaneous coronary interventions (PCI)—stenting clogged arteries—increasingly rely on seeing inside the vessel, not just looking at X-ray shadows. Philips already owns strong IVUS (intravascular ultrasound) technology. However, SpectraWAVE brings a different, complementary set of eyes: Enhanced Vascular Imaging (EVI).

This allows Philips to offer a “comprehensive clinician choice” model. Whether a doctor needs the depth penetration of ultrasound or the high-resolution surface detail of optical coherence tomography (OCT), Philips can now provide both within one integrated ecosystem.

Decoding the Tech: DeepOCT and NIRS

The jewel in this acquisition is SpectraWAVE’s HyperVue Imaging System. It combines two sophisticated technologies that have historically been fragmented:

  1. DeepOCT (Optical Coherence Tomography): Think of this as “ultrasound with light.” It provides microscopic detail of the artery wall structure.
  2. NIRS (Near-Infrared Spectroscopy): This analyzes the chemical composition of the plaque, identifying lipid-rich areas that are prone to rupture.

By combining these into a single catheter pullback with AI-automated analysis, SpectraWAVE (and now Philips) offers clinicians a rapid, detailed map of the “enemy” inside the artery. “This partnership allows us to integrate and scale HyperVue… supporting more consistent, high-quality care,” noted Eman Namati, PhD, CEO of SpectraWAVE.

The Wire-Free Revolution

Beyond imaging, the acquisition targets workflow efficiency with X1-FFR. Traditionally, measuring blood flow pressure (Fractional Flow Reserve, or FFR) required threading a specialized pressure wire into the artery—a physical intervention that takes time and costs money.

X1-FFR uses AI to calculate this pressure drop directly from the X-ray angiogram, with no wire required. This “angio-derived” physiology is a massive trend in cath labs because it reduces procedural complexity.

By adding X1-FFR alongside its existing OmniWire iFR (a wire-based technology), Philips is effectively cornering the market on physiology options. They can now offer wire-based precision for complex cases and wire-free speed for routine assessments, all guided by the same Azurion interface.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Healthcare Mergers & Acquisitions

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

2026 Predictions & Trends

Healthcare 2026 Forecast: Executives on AI Survival, Financial Reckoning, and the End of Point Solutions

2026 Healthcare Executive Predictions: Why the AI “Pilot Era” Is Officially Over

Most-Read

NYC Health + Hospitals to Acquire Maimonides in $2.2B Safety Net Overhaul

NYC Health + Hospitals to Acquire Maimonides in $2.2B Safety Net Overhaul

KLAS Report: Why Hospitals Are Choosing Efficiency Over 'Agentic' AI Hype in 2025

KLAS Report: Why Hospitals Are Choosing Efficiency Over ‘Agentic’ AI Hype in 2025

Advanced Primary Care 2026: Top 6 Investments for Health Systems According to Harvard Medical School

Advanced Primary Care 2026: Top 6 Investments for Health Systems According to Harvard Medical School

AI Nutrition Labels: The Key to Provider Adoption and Patient Trust?

AI Nutrition Labels: The Key to Provider Adoption and Patient Trust?

Kristen Hartsell, VP of Clinical Services, RedSail Technologies

The Pharmacy Closures Crisis: How Independent Pharmacies Are Fixing Pharmacy Deserts

HHS Launches 'OneHHS' AI Strategy to Integrate AI Across CDC, CMS, and FDA for Efficiency and Public Trust

HHS Launches ‘OneHHS’ AI Strategy to Integrate AI Across CDC, CMS, and FDA for Efficiency and Public Trust

From Overwhelmed to Optimized: How AI Agents Address Staffing Challenges and Burnout in Healthcare

From Overwhelmed to Optimized: How AI Agents Address Staffing Challenges and Burnout in Healthcare

The VBC Paradox: Why Hospitals Are Doubling Down on Value-Based Care While Revenue at Risk Lags

The VBC Paradox: Why Hospitals Are Doubling Down on Value-Based Care While Revenue at Risk Lags

Tebra Secures $250M to Challenge Legacy EHRs with AI-Powered Automation

Tebra Secures $250M to Challenge Legacy EHRs with AI-Powered Automation

AstraZeneca Selects Salesforce Agentforce Life Sciences to Deploy AI-Powered Global Customer Engagement

AstraZeneca Selects Salesforce Agentforce Life Sciences to Deploy AI-Powered Global Customer Engagement

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |